Publications
Found 2 results
Filters: Author is A. Fazaeli [Clear All Filters]
“The L55M polymorphism of paraoxonase-1 is a risk factor for rheumatoid arthritis”, vol. 9, pp. 1735-1741, 2010.
, Arnett FC, Edworthy SM, Bloch DA, McShane DJ, et al. (1988). The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 31: 315-324.
http://dx.doi.org/10.1002/art.1780310302
PMid:3358796
Aviram M, Rosenblat M, Bisgaier CL, Newton RS, et al. (1998). Paraoxonase inhibits high-density lipoprotein oxidation and preserves its functions. A possible peroxidative role for paraoxonase. J. Clin. Invest. 101: 1581-1590.
http://dx.doi.org/10.1172/JCI1649
PMid:9541487 PMCid:508738
Aviram M, Hardak E, Vaya J, Mahmood S, et al. (2000). Human serum paraoxonases (PON1) Q and R selectively decrease lipid peroxides in human coronary and carotid atherosclerotic lesions: PON1 esterase and peroxidase-like activities. Circulation 101: 2510-2517.
http://dx.doi.org/10.1161/01.CIR.101.21.2510
PMid:10831526
Baskol G, Demir H, Baskol M, Kilic E, et al. (2005). Assessment of paraoxonase 1 activity and malondialdehyde levels in patients with rheumatoid arthritis. Clin. Biochem. 38: 951-955.
http://dx.doi.org/10.1016/j.clinbiochem.2005.06.010
PMid:16055108
Bauerova K and Bezek A (1999). Role of reactive oxygen and nitrogen species in etiopathogenesis of rheumatoid arthritis. Gen. Physiol. Biophys. 18 (Spec No.): 15-20.
Blatter MC, James RW, Messmer S, Barja F, et al. (1993). Identification of a distinct human high-density lipoprotein subspecies defined by a lipoprotein-associated protein, K-45. Identity of K-45 with paraoxonase. Eur. J. Biochem. 211: 871-879.
http://dx.doi.org/10.1111/j.1432-1033.1993.tb17620.x
PMid:8382160
Deighton CM and Walker DJ (1991). The familial nature of rheumatoid arthritis. Ann. Rheum. Dis. 50: 62-65.
http://dx.doi.org/10.1136/ard.50.1.62
PMid:1994873 PMCid:1004331
Feingold KR, Memon RA, Moser AH and Grunfeld C (1998). Paraoxonase activity in the serum and hepatic mRNA levels decrease during the acute phase response. Atherosclerosis 139: 307-315.
http://dx.doi.org/10.1016/S0021-9150(98)00084-7
Gambhir JK, Lali P and Jain AK (1997). Correlation between blood antioxidant levels and lipid peroxidation in rheumatoid arthritis. Clin. Biochem. 30: 351-355.
http://dx.doi.org/10.1016/S0009-9120(96)00007-0
Gan KN, Smolen A, Eckerson HW and La Du BN (1991). Purification of human serum paraoxonase/arylesterase. Evidence for one esterase catalyzing both activities. Drug Metab. Dispos. 19: 100-106.
PMid:1673382
Garin MC, James RW, Dussoix P, Blanche H, et al. (1997). Paraoxonase polymorphism Met-Leu54 is associated with modified serum concentrations of the enzyme. A possible link between the paraoxonase gene and increased risk of cardiovascular disease in diabetes. J. Clin. Invest. 99: 62-66.
http://dx.doi.org/10.1172/JCI119134
PMid:9011577 PMCid:507768
Griffiths HR and Lunec J (1996). The C1q binding activity of IgG is modified in vitro by reactive oxygen species: implications for rheumatoid arthritis. FEBS Lett. 388: 161-164.
http://dx.doi.org/10.1016/0014-5793(96)00542-X
Halliwell B (1994). Free radicals, antioxidants, and human disease: curiosity, cause, or consequence? Lancet 344: 721-724.
http://dx.doi.org/10.1016/S0140-6736(94)92211-X
Hashemi M, Moazeni-Roodi AK, Fazaeli A, Sandoughi M, et al. (2010). Lack of association between paraoxonase-1 Q192R polymorphism and rheumatoid arthritis in southeast Iran. Genet. Mol. Res. 9: 333-339.
http://dx.doi.org/10.4238/vol9-1gmr728
PMid:20198589
Humbert R, Adler DA, Disteche CM, Hassett C, et al. (1993). The molecular basis of the human serum paraoxonase activity polymorphism. Nat. Genet. 3: 73-76.
http://dx.doi.org/10.1038/ng0193-73
PMid:8098250
Isik A, Koca SS, Ustundag B, Celik H, et al. (2007). Paraoxonase and arylesterase levels in rheumatoid arthritis. Clin. Rheumatol. 26: 342-348.
http://dx.doi.org/10.1007/s10067-006-0300-8
PMid:16642406
Jaswal S, Mehta HC, Sood AK and Kaur J (2003). Antioxidant status in rheumatoid arthritis and role of antioxidant therapy. Clin. Chim. Acta 338: 123-129.
http://dx.doi.org/10.1016/j.cccn.2003.08.011
PMid:14637276
Leviev I and James RW (2000). Promoter polymorphisms of human paraoxonase PON1 gene and serum paraoxonase activities and concentrations. Arterioscler. Thromb. Vasc. Biol. 20: 516-521.
http://dx.doi.org/10.1161/01.ATV.20.2.516
PMid:10669651
Leviev I, Negro F and James RW (1997). Two alleles of the human paraoxonase gene produce different amounts of mRNA. An explanation for differences in serum concentrations of paraoxonase associated with the (Leu-Met54) polymorphism. Arterioscler. Thromb. Vasc. Biol. 17: 2935-2939.
http://dx.doi.org/10.1161/01.ATV.17.11.2935
PMid:9409279
Mackness B, Mackness MI, Arrol S, Turkie W, et al. (1998). Effect of the human serum paraoxonase 55 and 192 genetic polymorphisms on the protection by high density lipoprotein against low density lipoprotein oxidative modification. FEBS Lett. 423: 57-60.
http://dx.doi.org/10.1016/S0014-5793(98)00064-7
Mackness MI, Mackness B, Durrington PN, Connelly PW, et al. (1996). Paraoxonase: biochemistry, genetics and relationship to plasma lipoproteins. Curr. Opin. Lipidol. 7: 69-76.
http://dx.doi.org/10.1097/00041433-199604000-00004
PMid:8743898
Maury CP, Junge W and Teppo AM (1984). Serum esterase activity in reactive systemic amyloidosis and its relation to amyloid A degrading activity. J. Lab. Clin. Med. 104: 761-766.
PMid:6092501
McKeown MJ, Hall ND and Corvalan JR (1984). Defective monocyte accessory function due to surface sulphydryl (SH) oxidation in rheumatoid arthritis. Clin. Exp. Immunol. 56: 607-613.
PMid:6744663 PMCid:1536001
Miesel R, Murphy MP and Kroger H (1996). Enhanced mitochondrial radical production in patients which rheumatoid arthritis correlates with elevated levels of tumor necrosis factor alpha in plasma. Free Radic. Res. 25: 161-169.
http://dx.doi.org/10.3109/10715769609149921
PMid:8885334
Nurcombe HL, Bucknall RC and Edwards SW (1991). Activation of the neutrophil myeloperoxidase-H2O2 system by synovial fluid isolated from patients with rheumatoid arthritis. Ann. Rheum. Dis. 50: 237-242.
http://dx.doi.org/10.1136/ard.50.4.237
PMid:1851410 PMCid:1004393
Popa C, van Tits LJ, Barrera P, Lemmers HL, et al. (2009). Anti-inflammatory therapy with tumour necrosis factor alpha inhibitors improves high-density lipoprotein cholesterol antioxidative capacity in rheumatoid arthritis patients. Ann. Rheum. Dis. 68: 868-872.
http://dx.doi.org/10.1136/ard.2008.092171
PMid:18635596
Primo-Parmo SL, Sorenson RC, Teiber J and La Du BN (1996). The human serum paraoxonase/arylesterase gene (PON1) is one member of a multigene family. Genomics 33: 498-507.
http://dx.doi.org/10.1006/geno.1996.0225
PMid:8661009
Ridderstad A, Abedi-Valugerdi M and Moller E (1991). Cytokines in rheumatoid arthritis. Ann. Med. 23: 219-223.
http://dx.doi.org/10.3109/07853899109148051
PMid:1930911
Rozenberg O, Rosenblat M, Coleman R, Shih DM, et al. (2003). Paraoxonase (PON1) deficiency is associated with increased macrophage oxidative stress: studies in PON1-knockout mice. Free Radic. Biol. Med. 34: 774-784.
http://dx.doi.org/10.1016/S0891-5849(02)01429-6
Sattar N, McCarey DW, Capell H and McInnes IB (2003). Explaining how "high-grade" systemic inflammation accelerates vascular risk in rheumatoid arthritis. Circulation 108: 2957-2963.
http://dx.doi.org/10.1161/01.CIR.0000099844.31524.05
PMid:14676136
Shih DM, Gu L, Xia YR, Navab M, et al. (1998). Mice lacking serum paraoxonase are susceptible to organophosphate toxicity and atherosclerosis. Nature 394: 284-287.
http://dx.doi.org/10.1038/28406
PMid:9685159
Tanimoto N, Kumon Y, Suehiro T, Ohkubo S, et al. (2003). Serum paraoxonase activity decreases in rheumatoid arthritis. Life Sci. 72: 2877-2885.
http://dx.doi.org/10.1016/S0024-3205(03)00195-4
Ye S, Dhillon S, Ke X, Collins AR, et al. (2001). An efficient procedure for genotyping single nucleotide polymorphisms. Nucleic Acids Res. 29: E88.
http://dx.doi.org/10.1093/nar/29.17.e88
PMid:11522844 PMCid:55900
Zwerina J, Redlich K, Schett G and Smolen JS (2005). Pathogenesis of rheumatoid arthritis: targeting cytokines. Ann. N. Y. Acad. Sci. 1051: 716-729.
http://dx.doi.org/10.1196/annals.1361.116
PMid:16127012
“Lack of association between paraoxonase-1 Q192R polymorphism and rheumatoid arthritis in southeast Iran”, vol. 9, pp. 333-339, 2010.
, Agrawal S, Tripathi G, Prajnya R, Sinha N, et al. (2009). Paraoxonase 1 gene polymorphisms contribute to coronary artery disease risk among north Indians. Indian J. Med. Sci. 63: 335-344.
http://dx.doi.org/10.4103/0019-5359.55884
PMid:19770524
Arnett FC, Edworthy SM, Bloch DA, McShane DJ, et al. (1988). The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 31: 315-324.
http://dx.doi.org/10.1002/art.1780310302
PMid:3358796
Aviram M, Rosenblat M, Bisgaier CL, Newton RS, et al. (1998). Paraoxonase inhibits high-density lipoprotein oxidation and preserves its functions. A possible peroxidative role for paraoxonase. J. Clin. Invest. 101: 1581-1590.
http://dx.doi.org/10.1172/JCI1649
PMid:9541487 PMCid:508738
Aviram M, Hardak E, Vaya J, Mahmood S, et al. (2000). Human serum paraoxonases (PON1) Q and R selectively decrease lipid peroxides in human coronary and carotid atherosclerotic lesions: PON1 esterase and peroxidase-like activities. Circulation 101: 2510-2517.
http://dx.doi.org/10.1161/01.CIR.101.21.2510
PMid:10831526
Baskol G, Demir H, Baskol M, Kilic E, et al. (2005). Assessment of paraoxonase 1 activity and malondialdehyde levels in patients with rheumatoid arthritis. Clin. Biochem. 38: 951-955.
http://dx.doi.org/10.1016/j.clinbiochem.2005.06.010
PMid:16055108
Bauerova K and Bezek A (1999). Role of reactive oxygen and nitrogen species in etiopathogenesis of rheumatoid arthritis. Gen. Physiol. Biophys. 18 (Spec No.): 15-20.
Blatter MC, James RW, Messmer S, Barja F, et al. (1993). Identification of a distinct human high-density lipoprotein subspecies defined by a lipoprotein-associated protein, K-45. Identity of K-45 with paraoxonase. Eur. J. Biochem. 211: 871-879.
http://dx.doi.org/10.1111/j.1432-1033.1993.tb17620.x
PMid:8382160
Deighton CM and Walker DJ (1991). The familial nature of rheumatoid arthritis. Ann. Rheum. Dis. 50: 62-65.
http://dx.doi.org/10.1136/ard.50.1.62
PMid:1994873 PMCid:1004331
Feingold KR, Memon RA, Moser AH and Grunfeld C (1998). Paraoxonase activity in the serum and hepatic mRNA levels decrease during the acute phase response. Atherosclerosis 139: 307-315.
http://dx.doi.org/10.1016/S0021-9150(98)00084-7
Gambhir JK, Lali P and Jain AK (1997). Correlation between blood antioxidant levels and lipid peroxidation in rheumatoid arthritis. Clin. Biochem. 30: 351-355.
http://dx.doi.org/10.1016/S0009-9120(96)00007-0
Gan KN, Smolen A, Eckerson HW and La Du BN (1991). Purification of human serum paraoxonase/arylesterase. Evidence for one esterase catalyzing both activities. Drug Metab. Dispos. 19: 100-106.
PMid:1673382
Garin MC, James RW, Dussoix P, Blanche H, et al. (1997). Paraoxonase polymorphism Met-Leu54 is associated with modified serum concentrations of the enzyme. A possible link between the paraoxonase gene and increased risk of cardiovascular disease in diabetes. J. Clin. Invest. 99: 62-66.
http://dx.doi.org/10.1172/JCI119134
PMid:9011577 PMCid:507768
Griffiths HR and Lunec J (1996). The C1q binding activity of IgG is modified in vitro by reactive oxygen species: implications for rheumatoid arthritis. FEBS Lett. 388: 161-164.
http://dx.doi.org/10.1016/0014-5793(96)00542-X
Halliwell B (1994). Free radicals, antioxidants, and human disease: curiosity, cause, or consequence? Lancet 344: 721-724.
http://dx.doi.org/10.1016/S0140-6736(94)92211-X
Humbert R, Adler DA, Disteche CM, Hassett C, et al. (1993). The molecular basis of the human serum paraoxonase activity polymorphism. Nat. Genet. 3: 73-76.
http://dx.doi.org/10.1038/ng0193-73
PMid:8098250
Isik A, Koca SS, Ustundag B, Celik H, et al. (2007). Paraoxonase and arylesterase levels in rheumatoid arthritis. Clin. Rheumatol. 26: 342-348.
http://dx.doi.org/10.1007/s10067-006-0300-8
PMid:16642406
Jaswal S, Mehta HC, Sood AK and Kaur J (2003). Antioxidant status in rheumatoid arthritis and role of antioxidant therapy. Clin. Chim. Acta 338: 123-129.
http://dx.doi.org/10.1016/j.cccn.2003.08.011
PMid:14637276
Leduc V and Poirier J (2008). Polymorphisms at the paraoxonase 1 L55M and Q192R loci affect the pathophysiology of Alzheimer's disease: emphasis on the cholinergic system and beta-amyloid levels. Neurodegener. Dis. 5: 225-227.
http://dx.doi.org/10.1159/000113709
PMid:18322397
Leduc V, Theroux L, Dea D, Robitaille Y, et al. (2009). Involvement of paraoxonase 1 genetic variants in Alzheimer's disease neuropathology. Eur. J. Neurosci. 30: 1823-1830.
http://dx.doi.org/10.1111/j.1460-9568.2009.06983.x
PMid:19863653
Mackness B, Mackness MI, Arrol S, Turkie W, et al. (1998). Effect of the human serum paraoxonase 55 and 192 genetic polymorphisms on the protection by high density lipoprotein against low density lipoprotein oxidative modification. FEBS Lett. 423: 57-60.
http://dx.doi.org/10.1016/S0014-5793(98)00064-7
Mackness MI, Mackness B, Durrington PN, Connelly PW, et al. (1996). Paraoxonase: biochemistry, genetics and relationship to plasma lipoproteins. Curr. Opin. Lipidol. 7: 69-76.
http://dx.doi.org/10.1097/00041433-199604000-00004
PMid:8743898
Maury CP, Junge W and Teppo AM (1984). Serum esterase activity in reactive systemic amyloidosis and its relation to amyloid A degrading activity. J. Lab. Clin. Med. 104: 761-766.
PMid:6092501
McKeown MJ, Hall ND and Corvalan JR (1984). Defective monocyte accessory function due to surface sulphydryl (SH) oxidation in rheumatoid arthritis. Clin. Exp. Immunol. 56: 607-613.
PMid:6744663 PMCid:1536001
Miesel R, Murphy MP and Kroger H (1996). Enhanced mitochondrial radical production in patients which rheumatoid arthritis correlates with elevated levels of tumor necrosis factor alpha in plasma. Free Radic. Res. 25: 161-169.
http://dx.doi.org/10.3109/10715769609149921
PMid:8885334
Newton CR, Graham A, Heptinstall LE, Powell SJ, et al. (1989). Analysis of any point mutation in DNA. The amplification refractory mutation system (ARMS). Nucleic Acids Res. 17: 2503-2516.
http://dx.doi.org/10.1093/nar/17.7.2503
PMid:2785681 PMCid:317639
Nurcombe HL, Bucknall RC and Edwards SW (1991). Activation of the neutrophil myeloperoxidase-H2O2 system by synovial fluid isolated from patients with rheumatoid arthritis. Ann. Rheum. Dis. 50: 237-242.
http://dx.doi.org/10.1136/ard.50.4.237
PMid:1851410 PMCid:1004393
Popa C, van Tits LJ, Barrera P, Lemmers HL, et al. (2009). Anti-inflammatory therapy with tumour necrosis factor alpha inhibitors improves high-density lipoprotein cholesterol antioxidative capacity in rheumatoid arthritis patients. Ann. Rheum. Dis. 68: 868-872.
http://dx.doi.org/10.1136/ard.2008.092171
PMid:18635596
Primo-Parmo SL, Sorenson RC, Teiber J and La Du BN (1996). The human serum paraoxonase/arylesterase gene (PON1) is one member of a multigene family. Genomics 33: 498-507.
http://dx.doi.org/10.1006/geno.1996.0225
PMid:8661009
Rozenberg O, Rosenblat M, Coleman R, Shih DM, et al. (2003). Paraoxonase (PON1) deficiency is associated with increased macrophage oxidative stress: studies in PON1-knockout mice. Free Radic. Biol. Med. 34: 774-784.
http://dx.doi.org/10.1016/S0891-5849(02)01429-6
Saremi MA, Saremi M and Tavallaei M (2008). Rapid genomic DNA extraction (RGDE). Forensic Sci. Int. Genet. Suppl. Ser. 1: 63-65.
Sattar N, McCarey DW, Capell H and McInnes IB (2003). Explaining how "high-grade" systemic inflammation accelerates vascular risk in rheumatoid arthritis. Circulation 108: 2957-2963.
http://dx.doi.org/10.1161/01.CIR.0000099844.31524.05
PMid:14676136
Shih DM, Gu L, Xia YR, Navab M, et al. (1998). Mice lacking serum paraoxonase are susceptible to organophosphate toxicity and atherosclerosis. Nature 394: 284-287.
http://dx.doi.org/10.1038/28406
PMid:9685159
Sidoti A, Antognelli C, Rinaldi C, D'Angelo R, et al. (2007). Glyoxalase I A111E, paraoxonase 1 Q192R and L55M polymorphisms: susceptibility factors of multiple sclerosis? Mult. Scler. 13: 446-453.
PMid:17463067
Tanimoto N, Kumon Y, Suehiro T, Ohkubo S, et al. (2003). Serum paraoxonase activity decreases in rheumatoid arthritis. Life Sci. 72: 2877-2885.
http://dx.doi.org/10.1016/S0024-3205(03)00195-4
Ye S, Dhillon S, Ke X, Collins AR, et al. (2001). An efficient procedure for genotyping single nucleotide polymorphisms. Nucleic Acids Res. 29: E88.
http://dx.doi.org/10.1093/nar/29.17.e88
PMid:11522844 PMCid:55900